Lei Tian, Zuojun Gao, Lei Zhu, Xiaoru Shi, Shaozhen Zhao, Hao Gu, Guoxing Xu, Linnong Wang, Hong Dai, Hong Zhang, Xiuming Jin, Ke Ma, Yonggen Xu, Lixiao Ma, Cheng Pei, Bilian Ke, Sonja Krösser, Yunxia Zhang, Ying Jie
IMPORTANCE: Meibomian gland dysfunction (MGD) is a leading cause of evaporative dry eye disease (DED). Medical and surgical management for DED is limited; therefore, new treatment options are sought. OBJECTIVE: To evaluate the efficacy and safety of SHR8058 (perfluorohexyloctane) eye drops in Chinese patients with DED associated with MGD through 57 days. DESIGN, SETTING, AND PARTICIPANTS: This was a randomized, multicenter, double-masked, saline-controlled, phase 3 clinical trial conducted from February 4, 2021, to September 7, 2022...
March 16, 2023: JAMA Ophthalmology